+Undoctored
Media release from The Lancet
Friday 16 July 2021, 12:02 PM
8 minutes to Read
• Study is most comprehensive of its kind and included more than 70,000 adults in the UK hospitalised with severe COVID-19 disease. Of these, half (36,367 of 73,197) developed one or more health complication during their hospitalisation.
• Most common complications included renal, complex respiratory, and systemic complications, but cardiovascular, neurological, and gastrointestinal and liver complications were also reported.
• The study found high rates of complications across all age groups. Men and those aged older than 60 years were most likely affected, but complications and poor functional outcomes were common, even in younger, previously healthy adults.
एक जुलाई पदक से सम्मानित होने वालों की कहानी
hindi.cri.cn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hindi.cri.cn Daily Mail and Mail on Sunday newspapers.
5G telemedicine offering wins GLOMO award at MWC
lightreading.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lightreading.com Daily Mail and Mail on Sunday newspapers.
PTI | Beijing | Updated: 29-06-2021 12:31 IST | Created: 29-06-2021 12:03 IST
Representative Image Image Credit: ANI
Country:
SHARE
Two doses of the China-made COVID-19 vaccine, CoronaVac, are safe and produce a strong antibody response among children and adolescents aged 3-17 years, according to a study published in The Lancet Infectious Diseases journal.
The phase 1/2 trial on 550 young people found that over 96 per cent of children and adolescents who received two doses of the vaccine, manufactured by Sinovac, developed antibodies against SARS-CoV-2, the virus that causes COVID-19.
Advertisement
Most adverse reactions were mild or moderate, with pain at the injection site the most commonly reported symptom, the researchers said.